Steering Committee: Shlomo Melmed, MB, ChB, MACP, Maria Fleseriu, MD, FACE, Irina Bancos, MD, Eliza B. Geer, MD, Ruth Clapauch, MD, PhD
This series of live CME-accredited educational events aims to educate healthcare professionals on the medical management of Cushing's Syndrome. It is open to all healthcare professionals who wish to enhance their knowledge in this area. The events will feature a pituitary care expert who will deliver live, in-person presentations. Interactive case-based discussions will be integrated throughout the sessions to illustrate how clinicians can effectively handle and monitor the treatment response for Cushing's Disease. By participating in this educational event, attendees will stay updated on recent advancements in managing Cushing's Syndrome and its complications and it will equip caregivers with improved skills to accurately identify and manage the condition.
Join us for a series of dinner events scheduled to be held in multiple cities throughout the country in 2023. The events will be hosted in Scottsdale in November, followed by New Orleans in December. To secure your spot, kindly click the register button below. Upon registration, you will receive a confirmation email containing the program details for your specific event date.
Upcoming Dates
The utilization of a live interactive format for discussing real-life cases will enhance attendees' comprehension of personalized treatment approaches, encompassing surgery, medical therapy, bilateral adrenalectomy, and radiation. Our primary focus will be on newly approved second-line treatment options customized to suit individual patient requirements, along with the most effective biochemical markers for evaluating treatment response. This approach aims to optimize medical therapy outcomes and enhance patients' overall quality of life. Active participation in this discussion will enable attendees to distinguish between glucocorticoid withdrawal and adrenal insufficiency, which can be challenging to differentiate solely based on clinical symptoms. By gaining a better understanding of these distinctions, healthcare professionals can make well-informed decisions regarding patient management.
The program will also emphasize the significance of effectively managing comorbidities and symptoms in individuals with hypercortisolemia resulting from an ACTH-secreting pituitary adenoma. This aspect holds particular importance since patients with Cushing's Disease encounter various physical and emotional symptoms that significantly hinder their overall well-being and quality of life..
Upon completion of this program, attendees will be able to:
Accurately prescribe recently approved second-line treatment therapies tailored to meet unique patient needs, including the best biochemical markers, for assessing treatment response
Optimize medical therapy treatment outcomes for patients and improve their quality of life
Distinguish features of glucocorticoid withdrawal from adrenal insufficiency, which can be somewhat difficult to differentiate clinically.
Define the importance of comorbidities and symptoms management in patients with hypercortisolemia due to an ACTH-secreting pituitary adenoma.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Endocrine Society and the American College of Osteopathic Family Physicians. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 Credit
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates each event for a maximum of 1.00 AMA PRA Category 1™ Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
For questions about obtaining AMA PRA credit, please contact the Endocrine Society at info@endocrine.org.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
ABIM-MOC Points
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Meet the Steering Committee
Shlomo Melmed, MB, ChB, MACP
(Program Chair)
Professor & Dean
Cedars Sinai Medical Center
Disclosures:
Consultant - Ionis; Ipsen; Novo Nordisk; Recordati
Grant Recipient - Recordati
Eliza Geer, MD
Associate Professor
Memorial Sloan Kettering
Disclosures:
Advisory Board - Strongbridge/Xeris; HRA Pharma; Chiasma/Amryt
Grant Recipient - Strongbridge/Xeris; Sparrow; Corcept; Recordati; Ionis
Consultant - Strongbridge/Xeris
Irina Bancos, MD
Endocrinologist
Mayo Clinic
Disclosures:
Consultant - HRA Pharma; Corcept; Sparrow; Recordati
Advisory Board - HRA Pharma; Corcept; Recordati; Strongbridge
Ruth Clapauch, MD, PhD
(Peer Reviewer)
Professor
Unilago Uniao das Faculdades dos Grandes Lagos
No disclosures
Meet the Moderators
Ana Abreu, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
No disclosures
Shobana Athimulam, MD, MRCP
Assistant Professor and Senior Staff Physician
Henry Ford Hospital
No disclosures
John Carmichael, MD
Associate Professor of Clinical Medicine
Keck School of Medicine
University of Southern California
Disclosures:
Advisory Board - Novo Nordisk; Recordati; Camarus
Principal Investigator - Chiasma; Crinetics
Diane Donegan, MD
Assistant Professor
Indiana University
Disclosures:
Advisory Board - Corcept; Recordati
Investigator - Corcept
Database Participant - Amryt
Oksana Hamidi, DO
Assistant Professor
Division of Endocrinology and Metabolism
UT Southwestern Medical Center
Disclosures:
Advisory Board - Corcept; Pfizer
Larry Katznelson, MD
Professor of Neuroendocrinology and Medicine
Stanford University
Disclosures:
Advisory Board - Pfizer; Novo Nordisk; Strongbridge; Recordati
Research Investigator - Novartis; Camarus
Roberto Salvatori, MD
Medical Director
Johns Hopkins Pituitary Center
Professor
Johns Hopkins University School of Medicine
Disclosures:
Advisory Board - Novo Nordisk; Strongbridge; Ipsen; HRA Pharma
Clinical Trials Investigator - Corcept; Crinetics; Chiasma; Ascendis
Kevin Yuen, MBChB, MD, FRCP (UK), FACE, FEAA
Medical Director
Barrow Pituitary Center and Barrow Neuroendocrinology Clinic
Professor, Department of Neurology
Barrow Neurological Institute
Disclosures:
Advisory Board - Novo Nordisk; Ascendis; Corcept; Ipsen; Amryt; Crinetics; Recordati; Xeris
Grant Recipient - Crinetics; Ascendis; Corcept; Amryt
Speaker - Novo Nordisk; Recordati; Novo Nordisk
Maria Fleseriu, MD, FACE
Professor, Pituitary Center, Endocrinology and Neurosurgical Surgery
Oregon Health & Science University
Disclosures:
Consultant - Amryt; Ascendis; HRA Pharma; Ipsen; Novo Nordisk; Pfizer; Recordati; Xeris
Grant Recipient - Amryt; Ascendis; Crinetics; Ionis; Recordati; Xeris
Susan Samson, MD, PhD
Chair, Division of Endocrinology, Diabetes and Metabolism
Department of Medicine
Mayo Clinic
No disclosures